BIIB033 In Acute Optic Neuritis (AON)

计划入组 82 人 · 首次发布于 2012 年 11 月 4 日

Long-Term Assessment of Remyelinating Therapy

计划入组 52 人 · 首次发布于 2016 年 1 月 18 日

Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes

计划入组 28 人 · 首次发布于 2016 年 7 月 14 日

Multiple sclerosis/optic neuritis therapeutics (Find therapeutics)

Multiple sclerosis and optic neuritis based therapeutics (Conectus)

optic nerve disease therapeutics

Oculis

Switzerland

Orthocell Ltd

VistaGen Therapeutics

United States

Oculis' OCS-05 Shows Promise in Phase 2 Trial for Acute Optic Neuritis

FDA Grants Breakthrough Therapy Designation to Oculis' Privosegtor for Optic Neuritis Treatment

Oculis Strengthens Leadership with Appointment of Two World-Renowned Ophthalmology Experts as Chief Medical Advisors